Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022
October 31, 2022 07:00 ET
|
Applied Therapeutics
Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodelingBaseline analysis of Phase 3 ARISE-HF study supports...
Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy
October 25, 2022 07:00 ET
|
Applied Therapeutics
ARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placeboPrimary...
Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format
October 06, 2022 07:00 ET
|
Applied Therapeutics
• The study did not yet reach statistical significance at 12 months of treatment; however, AT-007 (gavorostat) demonstrated a trend in clinical benefit vs. placebo• Applied Therapeutics plans to meet...
Applied Therapeutics Reports Second Quarter 2022 Financial Results
August 12, 2022 07:00 ET
|
Applied Therapeutics
Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in...
Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference
July 28, 2022 07:00 ET
|
Applied Therapeutics
Gold sponsor of the 2022 Galactosemia Foundation Conference; new website and educational resources as part of ongoing commitment to the Galactosemia communityApplied Therapeutics to present research...
Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
June 22, 2022 22:12 ET
|
Applied Therapeutics
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates...
Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants
June 22, 2022 16:10 ET
|
Applied Therapeutics
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates...
Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia
June 03, 2022 07:00 ET
|
Applied Therapeutics
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics to Present at the UBS Global Healthcare Conference
May 19, 2022 07:00 ET
|
Applied Therapeutics
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics Reports First Quarter 2022 Financial Results
May 12, 2022 06:59 ET
|
Applied Therapeutics
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...